Blood test predicts Parkinson’s disease up to 7 years before symptom onset
Researchers have used a machine learning approach to create a panel of eight blood biomarkers that can identify people at risk for developing Parkinson’s disease up to 7 years before the first signs or symptoms.
Motor benefits for prasinezumab in rapidly progressing early-stage PD
Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, has shown promise for slowing motor progression in patients with rapidly progressing Parkinson’s disease in a post-hoc analysis of the PASADENA phase 2 study.
SMA newborn screening improves functional outcomes
Children diagnosed with spinal muscular atrophy through a newborn screening initiative have better functional outcomes than their peers diagnosed after the development of clinical symptoms, the SMARTCARE study findings show.
Lixisenatide slows motor disability progression in early PD
The glucagon-like peptide-1 receptor agonist lixisenatide slows motor disability progression in patients with early Parkinson’s disease, suggest findings from the LIXIPARK trial.
‘No substantive increase’ in ASD with prenatal topiramate exposure
Children born to women with epilepsy who take topiramate during the second half of their pregnancy do not have a substantially increased risk of autism spectrum disorder, suggests research published in The New England Journal of Medicine.
Blood immunoassay shows high diagnostic accuracy for Alzheimer’s disease pathology
A commercially available plasma phosphorylated (p)-tau217 immunoassay outperforms other biomarkers in accurately identifying biological Alzheimer’s disease, suggest findings from a study across three observational cohorts.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cerliponase alfa treatment shows extended efficacy for CLN2 disease
Cerliponase alfa treatment slows the progression of neuronal ceroid lipofuscinosis type 2 disease for at least 5 years, shows an open-label extension study in The Lancet Neurology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Plasma p-tau217 may help select Alzheimer’s disease patients for anti-amyloid immunotherapy
Plasma phosphorylated (p)-tau217 may be an effective biomarker for identifying patients with Alzheimer’s disease who are most likely to benefit from anti-amyloid immunotherapies based on amyloid (A)β positivity and tau pathology, say investigators.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Young age reduces MS disability but does not fully protect against it
Progression of multiple sclerosis in the absence of relapses can occur at any age, although it is less common in children than adults with the condition, suggests research.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cognitive decline continues during gantenerumab therapy for Alzheimer’s disease
Gantenerumab has failed to significantly slow cognitive impairment in people with early Alzheimer’s disease in the GRADUATE I and II trials of the anti-Aβ immunoglobulin G1 antibody.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
